Latest Non Small Cell Lung Cancer News

Page 1 of 5
Algorae Pharmaceuticals has moved closer to its first expected NSW Health supply orders while reporting stronger preclinical results from its AOS2 drug-discovery platform. The company ended September with $3.15 million in cash and a further $3 million undrawn facility, but its commercial contract carries no minimum volume commitment.
Victor Sage
Victor Sage
30 Oct 2026
Amplia Therapeutics is preparing the next stage of narmafotinib’s pancreatic cancer development as its ACCENT trial nears completion and a Lilly collaboration broadens the drug’s potential into lung cancer. The biotech ended September with $20.8 million in cash, rising to $25.6 million pro forma after an October R&D tax refund.
Victor Sage
Victor Sage
28 Oct 2026
Immutep’s pivotal TACTI-004 lung cancer trial dominates a difficult FY26, with the failure widening the loss to A$79.3 million and triggering an impairment, cost cuts and a root cause review. The biotech retains A$68.9 million in cash, cash equivalents and term deposits, while its remaining investment case rests on IMP761 and selected efti studies.
Ada Torres
Ada Torres
27 Oct 2026
Immutep’s FY2026 filing puts the full cost of the failed TACTI-004 Phase III trial on display: a larger loss, an impaired efti asset and a manufacturing investigation that remains unresolved. The company has A$68.9 million in cash and term deposits, which it forecasts will fund operations into the first half of calendar 2028 under current plans.
Ada Torres
Ada Torres
26 Oct 2026
Amplia Therapeutics has received an A$4.78 million refundable R&D tax rebate, giving the clinical-stage biotechnology company additional cash to advance its FAK inhibitor programs. The funds will support multiple narmafotinib trials and related research, including studies involving Lilly.
Victor Sage
Victor Sage
22 Oct 2026
Racura Oncology says both Phase 1 RC220 programs have cleared their opening dose cohorts without dose-limiting toxicities, while its Korean expansion broadens the CPACS trial. The company ended September with $30.7 million in cash, which management says funds committed activities into mid-2028.
Victor Sage
Victor Sage
22 Oct 2026
Radiopharm Theranostics reported a A$56.3 million comprehensive loss for fiscal 2026, with operating cash outflows rising to A$52.8 million and cash falling to A$4.1 million. The company says further funding is required, while auditors flag a material uncertainty over its ability to continue as a going concern.
Victor Sage
Victor Sage
30 Sept 2026
Racura Oncology's FY2026 results reveal a widening loss despite a 22% revenue dip, underpinned by significant scientific progress on its lead drug targeting the elusive MYC gene and a robust $34.3 million cash position.
Ada Torres
Ada Torres
25 Aug 2026
Amplia Therapeutics has teamed up with Eli Lilly to test its FAK inhibitor narmafotinib alongside Lilly’s KRAS G12C inhibitor olomorasib in advanced non-small cell lung cancer, marking a strategic expansion beyond pancreatic and ovarian cancers.
Ada Torres
Ada Torres
4 Aug 2026
Racura Oncology has hit key clinical milestones in its RC220 development, including first patient dosing in a lung cancer trial and dose escalation in a cardioprotection study, supported by a strong $34.3 million cash position.
Ada Torres
Ada Torres
28 July 2026
Immutep’s INSIGHT-003 trial shows promising overall survival in first-line non-squamous NSCLC, yet the Phase III TACTI-004 trial was discontinued following a futility analysis. Ongoing root cause investigations aim to clarify the divergent outcomes.
Ada Torres
Ada Torres
13 July 2026
Racura Oncology has secured Bellberry HREC approval for its HARNESS-1 lung cancer trial, enabling expansion to additional Australian sites including Chris O’Brien Lifehouse and Austin Health, setting the stage for accelerated patient enrolment.
Ada Torres
Ada Torres
3 July 2026

Browse the archive

Full archive